Sold as Hypaque, Hypaque Sodium 20%. Every FDA application for this active ingredient: 2 branded and 2 generic.
As of Nov 16, 2026, FDA lists 4 applications for Diatrizoate Sodium (sold as Hypaque, Hypaque Sodium 20%), first approved Nov 26, 1954, with 0 new uses approved and 0 published complete response letters.
| Study | Phase | Status | Posted |
|---|---|---|---|
| Optimizing Treatment of Adhesive Small Bowel ObstructionAdhesive Small Bowel Obstruction · University of California, Los Angeles | Phase 3 | Recruiting | Dec 26, 2023 |
| Nov 26, 1954 | Hypaque, Hypaque Sodium 20%NDA 9561 · New molecular entity | Ge Healthcare | 50 | Discontinued |
| Mar 26, 1956 | HypaqueNDA 11386 · New dosage form | Ge Healthcare | 19 | Discontinued |
| Sep 23, 1982 | Urovist Sodium 300ANDA 87725 | Bayer Hlthcare | 2 | Discontinued |
| — | Md-50ANDA 87075 | Mallinckrodt | 2 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA